Skip to Content
Merck
All Photos(1)

Key Documents

Y0000475

Carboprost trometamol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxy-15- methylprosta-5,13-dien-1-oic acid with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), Carboprost tromethamine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H47NO8
CAS Number:
Molecular Weight:
489.64
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

carboprost

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

InChI

1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5+,14-12-;/t16-,17?,18+,19-,21-;/m0./s1

InChI key

UMMADZJLZAPZAW-QFXCEMDRSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carboprost trometamol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L A Levine et al.
The Journal of urology, 149(4), 719-723 (1993-04-01)
We review our experience with 18 consecutive patients who received intravesical carboprost tromethamine, an F2-alpha prostaglandin, for severe hemorrhagic cystitis following cyclophosphamide chemotherapy. Of the patients 16 were given cyclophosphamide for conditioning before bone marrow transplantation and 2 received the
Combined bladder and uterine rupture following prostaglandin-induced midtrimester abortion: an unreported event.
Umber Agarwal et al.
Acta obstetricia et gynecologica Scandinavica, 82(10), 974-975 (2003-09-06)
R F Lamont et al.
Prostaglandins & other lipid mediators, 66(3), 203-210 (2001-10-02)
In a prospective, open-label, assessor-blind, randomised parallel group study the efficacy and safety of Hemabate (Pharmacia-Upjohn Pharmaceuticals, Milton Keynes, Buckinghamshire) an analogue of 15-methyl-prostaglandin (PGF2alpha) analogue was compared with Syntometrine (Alliance Pharmaceuticals, Chippenham, Wilts) the standard combination of ergometrine and
D M Kranc et al.
The Journal of urology, 148(4), 1326-1330 (1992-10-01)
Recently, prostaglandins have been shown to be effective agents for the treatment of cyclophosphamide-induced hemorrhagic cystitis. Among the prostaglandins studied is carboprost tromethamine, a PGF2a analog. To determine the effectiveness of carboprost tromethamine therapy on the urothelium, we induced hemorrhagic
Postpartum hemorrhage: new management options.
Gary A Dildy
Clinical obstetrics and gynecology, 45(2), 330-344 (2002-06-06)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service